Syros Pharmaceuticals Stock In The News
| SYRS Stock | USD 0.27 0.02 8.00% |
Our overall analysis of Syros Pharmaceuticals' news coverage and content from conventional and social sources shows investors' bearish mood towards Syros Pharmaceuticals. The specific impact of Syros Pharmaceuticals news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Syros Pharmaceuticals' overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Syros Pharmaceuticals headlines in addition to utilizing other, more conventional financial analysis modules. Check out Syros Pharmaceuticals Backtesting and Syros Pharmaceuticals Hype Analysis. For more information on how to buy Syros Stock please use our How to Invest in Syros Pharmaceuticals guide.
Syros |
Syros Pharmaceuticals Today Top News and Investor Outlook
Syros Pharmaceuticals Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Syros and other traded companies coverage with news coverage. We help investors stay connected with Syros headlines for the 28th of November to make an informed investment decision based on correlating the impacts of news items on Syros Stock performance. Please note that trading solely based on the Syros Pharmaceuticals hype is not for everyone as timely availability and quick action are needed to avoid losses.
Syros Pharmaceuticals stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Syros earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Syros Pharmaceuticals that are available to investors today. That information is available publicly through Syros media outlets and privately through word of mouth or via Syros internal channels. However, regardless of the origin, that massive amount of Syros data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Syros Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Syros Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Syros Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Syros Pharmaceuticals alpha.
Syros Largest EPS Surprises
Earnings surprises can significantly impact Syros Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-08-08 | 2023-06-30 | -1.13 | -1.3 | -0.17 | 15 | ||
2024-07-31 | 2024-06-30 | -0.77 | -0.59 | 0.18 | 23 | ||
2023-05-10 | 2023-03-31 | -1.09 | -0.85 | 0.24 | 22 | ||
2023-11-14 | 2023-09-30 | -1.14 | -1.43 | -0.29 | 25 | ||
2020-05-07 | 2020-03-31 | -4.34 | -3.9 | 0.44 | 10 | ||
2020-11-05 | 2020-09-30 | -3.84 | -4.3 | -0.46 | 11 |
Syros Pharmaceuticals Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Syros Pharmaceuticals Stock. The global stock market is bearish. About 62% of major world exchanges and indexes are down. See today's market update for more information.
26th of November 2024
Kia Syros Compact SUV To Get Panoramic Sunroof- Teaser Confirms at ndtv.com
20th of November 2024
Syros Pharmaceuticals CEO Chee Conley sells shares worth 26,932 at investing.com
18th of November 2024
Syros Pharmaceuticals announces major company changes at investing.com
15th of November 2024
Avidity Partners Management LPs Strategic Acquisition in Syros Pharmaceuticals Inc at gurufocus.com
13th of November 2024
TD Cowen downgrades Syros Pharma stock to Hold on trial failure at investing.com
12th of November 2024
Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Ris... at businesswire.com
7th of November 2024
Acquisition by Fanucci Marsha of 4000 shares of Syros Pharmaceuticals subject to Rule 16b-... at MacroaxisInsider
21st of October 2024
Syros Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Impacted Sharehol... at accesswire.com
24th of September 2024
The Schall Law Firm Encourages Shareholders With Losses In Syros Pharmaceuticals, Inc. To ... at accesswire.com
12th of September 2024
Acquisition by Jason Haas of 45344 shares of Syros Pharmaceuticals at 1.6762 subject to Ru... at gurufocus.com
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Syros Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Syros Pharmaceuticals' short interest history, or implied volatility extrapolated from Syros Pharmaceuticals options trading.
Additional Tools for Syros Stock Analysis
When running Syros Pharmaceuticals' price analysis, check to measure Syros Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syros Pharmaceuticals is operating at the current time. Most of Syros Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syros Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syros Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syros Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.